- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 23.04. | GPW Benchmark: Communique - SYN2BIO | 1 | PAP | ||
| 15.04. | Syn2bio expects cardiomarker trial to be completed within next few months in Europe | 1 | PAP | ||
| 15.04. | Syn2bio debuts on Warsaw Stock Exchange | 1 | PAP | ||
| 08.04. | Syn2bio to debut on Warsaw Stock Exchange on April 15 | 5 | PAP | ||
| SYN2BIO Aktie jetzt für 0€ handeln | |||||
| 19.03. | Synektik's EGM approves company's split, followed by spin-off of cardiac biomarker project to Syn2bio | 3 | PAP | ||
| 16.03. | Syn2bio sees partnership agreements as main source of revenue; no share issue planned | 1 | PAP |
6 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 78,95 | -1,07 % | Curevac-Gründer wirft Biontech Täuschung vor | TÜBINGEN/MAINZ (dpa-AFX) - Nach der Übernahme des Biotechunternehmens Curevac durch Biontech wirft Curevac-Gründer Ingmar Hoerr dem Konkurrenten Täuschung vor. Hintergrund sind die Schließungspläne... ► Artikel lesen | |
| VIKING THERAPEUTICS | 26,950 | +0,94 % | Viking Therapeutics, Inc.: Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update | Conference call scheduled for 4:30 p.m. ET today
-- Phase 3 VANQUISH Trials for Subcutaneous VK2735 in Obesity Advance; VANQUISH-1 and VANQUISH-2 Trials Fully Enrolled... ► Artikel lesen | |
| KUROS BIOSCIENCES | 22,780 | +9,41 % | Kuros Biosciences AG: Kuros Biosciences appoints I.V. Hall as Chief Operating Officer, deepening operational, R&D and extremities leadership for next phase of growth | Kuros Biosciences appoints I.V. Hall as Chief Operating Officer, deepening operational, R&D and extremities leadership for next phase of growth
Schlieren (Zurich), Switzerland, May 7, 2026 - Kuros... ► Artikel lesen | |
| ABIVAX | 103,00 | -0,77 % | EQS-News: ABIVAX: Abivax Announces Results of its May 11, 2026 Annual General Meeting | EQS-News: ABIVAX
/ Key word(s): AGM/EGM
Abivax Announces Results of its May 11, 2026 Annual General Meeting
11.05.2026 / 22:05 CET/CEST
The issuer is solely responsible... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 1,435 | +2,43 % | Cardiff Oncology, Inc.: Cardiff Oncology Announces Key Leadership Appointments to Strengthen Executive Team for Next Phase of Growth | Board member and Interim CEO Mani Mohindru, PhD, named President and Chief Executive OfficerAppoints industry veterans Josh Muntner as Chief Financial Officer and Ajay Aggarwal, MD, MBA, as Chief... ► Artikel lesen | |
| IOVANCE BIOTHERAPEUTICS | 3,090 | +1,64 % | Iovance Biotherapeutics, Inc.: Iovance Biotherapeutics Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate Updates | 1Q26 Total Revenue of ~$71M Delivers ~45% Year-over-Year Growth 2Q26 Revenue Guidance of $86M to $88M and FY26 of $350M to $370M 40% Confirmed Objective Response Rate in Metastatic Serous Endometrial... ► Artikel lesen | |
| ARGENX | 680,00 | -1,71 % | Muskelschwäche-Medikament Vyvgart treibt Biotechunternehmen Argenx weiter an | AMSTERDAM (dpa-AFX) - Der starke Lauf seines Muskelschwäche-Medikaments Vyvgart hat dem Biotechspezialisten Argenx auch zum Jahresstart Schub verliehen. Der Konzernumsatz - der sich aktuell noch nahezu... ► Artikel lesen | |
| DENALI THERAPEUTICS | 16,450 | -0,75 % | Denali Therapeutics GAAP EPS of -$0.69 | ||
| INSMED | 99,64 | +0,85 % | Insmed Posts Narrower Loss In Q1 | WASHINGTON (dpa-AFX) - Insmed (INSM) reported a first quarter net loss of $163.6 million, or $0.76 per share, compared to a net loss of $256.6 million, or $1.42 per share, a year ago. Product... ► Artikel lesen | |
| CAPRICOR | 25,400 | -5,29 % | Capricor stock price target held at $63 by B.Riley on FDA progress | ||
| REVOLUTION MEDICINES | 128,10 | +3,18 % | Revolution Medicines, Inc.: Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate Progress | Daraxonrasib demonstrated unprecedented survival benefit in Phase 3 RASolute 302 trial in previously treated metastatic pancreatic cancer; detailed results will be presented in upcoming ASCO Plenary... ► Artikel lesen | |
| ZEVRA THERAPEUTICS | 9,400 | +2,17 % | Zevra outlines Celiprolol interim analysis trigger at 28 events while expanding MIPLYFFA access | ||
| SYNDAX PHARMACEUTICALS | 17,655 | +1,55 % | Syndax Pharmaceuticals, Inc.: Syndax Highlights 12 Revuforj (revumenib) Abstracts Accepted for EHA 2026, Advancing Leadership in Menin Inhibition | ||
| PALVELLA THERAPEUTICS | 104,00 | -2,80 % | Palvella Therapeutics Inc.: Palvella Therapeutics Announces Uplisting to the Nasdaq Global Market | Uplisting reflects Palvella's continued progress advancing potential first-in-disease therapies for serious, rare skin diseases and vascular malformations WAYNE, Pa., May 13, 2026 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| CORVUS PHARMACEUTICALS | 13,425 | -0,04 % | Corvus Pharmaceuticals, Inc. - S-8, Securities to be offered to employees in employee benefit plans |
Das Unternehmen SYN2BIO SA kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SYN2BIO SA finden Sie auf Wallstreet Online.